NASDAQ Composite opens in less than one hour and Novavax‘s pre-market value is already 6.84% down.
The last session, NASDAQ Composite finished with Novavax sliding 4.94% to $171.74. NASDAQ Composite slid 0.37% to $13,582.42, after four successive sessions in a row of losses, on what was a somewhat negative trend exchanging session.
Novavax’s last close was $180.67, 93.13% under its 52-week high of $331.68.
Novavax’s sales growth is 6826.3% for the current quarter and 1558.1% for the next. The company’s growth estimates for the present quarter is a negative 520.7% and positive 250% for the next.
Novavax’s last day, last week, and last month’s current volatility was 8.00%, 7.60%, and 5.43%, respectively.
Novavax’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 12.92% (day), 12.43% (last week), and 9.35% (last month), respectively.
Previous days news about Novavax
Novavax begins testing its Covid-19 vaccine candidate in teens. According to MarketWatch on Monday, 3 May, "Shares of Novavax Inc. gained 0.6% in trading on Monday after the biotechnology firm said it has expanded its Phase 3 clinical trial for its COVID-19 vaccine candidate to include 12 to 17 year olds in the U.S. Novavax’s experimental vaccine is currently being tested in a late-stage trial that began in December in the U.S. and Mexico. "
More news about Novavax.